Skip Navigation

Molecular envoys pave the way for pancreatic cancer to invade the liver

March 6, 2019 This article courtesy of Nature News.

Pancreatic cancer usually spreads to the liver. The identification of signals from cells adjacent to pancreatic tumours that boost liver colonization might suggest ways to block this deadly form of cancer invasion.

Pancreatic cancer is rapidly lethal, and the five-year post-diagnosis survival rate in the United States is 8%. At diagnosis, the cancer has usually already spread beyond its primary pancreatic site to invade other parts of the body, most commonly the liver. This renders futile the option of surgically removing the pancreatic tumour to prevent such lethal spread, or metastasis. Writing in Nature, Lee et al. report their identification, in mice and humans, of molecules made in the pancreas that travel to the liver and alter its environment to create conditions that assist cancer-cell invasion.

Much remains to be uncovered about the signals and sequence of events that precede and facilitate establishment of the implantation site for tumour invasion — known as the pro-metastatic niche5. Alterations that enable niche formation include blood-vessel changes that create cancer-cell docking sites and modifications to the layer of endothelial cells that form an outer barrier around tissues and that must be crossed for tissue invasion.

Although metastasis is usually the main reason for the failure of cancer treatment and for eventual death, it is a remarkably inefficient process. Cancers release millions of cells into the bloodstream each day, yet studies of skin cancer in animal models indicate that fewer than 0.1% of tumour cells form metastases. For metastasis to be successful, cancer cells must exit their primary site, enter the bloodstream and overcome challenges that include surviving physical stress in blood vessels, adapting to the unfamiliar cellular surroundings of a different host organ, and evading destruction by immune cells. Therefore, understanding the factors that create a pro-metastatic niche are of crucial importance for clarifying how cancer cells overcome such obstacles to become established at a distant site.

Lee and colleagues investigated how pancreatic-tumour cells generate the pro-metastatic niche. The authors demonstrate that, in mice, the protein interleukin 6 (IL-6), a type of immune-signalling molecule called a cytokine, is secreted from non-cancerous fibroblast cells in the microenvironment of the pancreatic tumour cells (Fig. 1). Fibroblasts are the main cells of the connective tissue. The authors report that IL-6 binds to its receptor protein on liver cells and drives expression of the transcription-factor protein STAT3, which is then activated by undergoing phosphorylation (the addition of a phosphate group). Liver cells that express such activated STAT3 secrete the proteins SAA1 and SAA2, which prepare the liver for the influx of cancer cells. The SAA proteins attract myeloid cells, which dampen the body’s immune-surveillance response by secreting cytokines that inhibit cancer-killing T cells. SAA1 and SAA2 also drive the activation of hepatic stellate cells, a type of liver cell that deposits extracellular-matrix material, thereby aiding the initial anchoring and sustenance of metastatic cancer cells.

When the authors blocked any of the signalling components that promote pro-metastatic-niche formation (IL-6 from fibroblasts, or STAT3, SAA1 or SAA2 from liver cells), the metastatic burden in animal models of pancreatic cancer was substantially reduced without affecting pancreatic-tumour growth, compared with the metastatic burden in animals in which the action of these signalling components wasn’t interrupted. The disruption of these signalling components did not stop pancreatic cancer from invading the lung, confirming the idea that metastatic-site specificity can be driven by signalling cascades that are extrinsic to the cancer cell, and not just by intrinsic molecular changes in the tumour. Lee and colleagues report that people who had pancreatic cancer and liver metastases, and those who had liver metastases arising from other types of primary tumour, such as lung or colorectal cancer, had higher than normal levels of SAA proteins in their bloodstream.

Lee and colleagues’ work clearly demonstrates how a pro-metastatic niche is established in the liver, but it is also worth considering the role of other possible mediators of pancreatic cancer’s ‘advance team’. For example, vesicles called exosomes are released by these cancer cells and travel to the liver, where they release a protein called MIF that initiates pro-metastatic-niche formation. Although Lee and colleagues did not measure exosome migration, they report that disruption of IL-6-mediated signalling did not affect the levels of MIF, suggesting that these two systems for driving pro-metastatic-niche formation might have non-overlapping roles. Indeed, a phenomenon as intricate as formation of the niche probably relies on a robustly regulated process that includes back-up mechanisms, and there are probably subtle differences in how the various pathways function. This is worth remembering, because it could explain why striking effects observed in animal models are often not replicated in humans.

What relevance do these findings have for the clinical treatment of pancreatic cancer? The disease stands out from other solid (non-blood cell) tumours in its tendency to form metastases early in the disease, when the tumour is small. This characteristic of early spread could explain why people in whom visible metastases are absent, and whose pancreatic tumour has been surgically removed, nevertheless soon develop liver metastases. Could treatment that targets pro-metastatic-niche formation, such as the use of an inhibitor of STAT3 or an antibody that blocks IL-6 binding to its receptor, be effective? Blocking the signalling system that enables a pro-metastatic niche to develop would probably be most useful just after the surgery to remove the tumour, when visible metastases are absent but the foundations of a metastatic niche are probably being established. There might then be a small window of opportunity to effectively interrupt niche formation.

Like any other promising observation in an animal model, these discoveries should be investigated further. Although there have been steady improvements in survival for people who have this type of tumour, the opportunity is ripe for a clinical trial to investigate the effects of targeting the pro-metastatic niche in pancreatic cancer.


Need Assistance?

If you need help or have a question please use the links below to help resolve your problem.